Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. reports developments in biotechnology and precision intracellular drug delivery through its proprietary Accum® platform. Company news centers on cancer-therapy applications, including antibody-drug conjugates, radiopharmaceutical and radio-immunoconjugate programs, and other complex biologics designed for intracellular and nuclear delivery.
Recurring updates also cover scientific advisory activity, industry presentations, collaboration work such as its program with Canadian Nuclear Laboratories, partnership outreach, and capital-structure actions including private placements, warrant amendments, and restricted stock unit grants.
Defence Therapeutics (OTCQB: DTCFF) announced that its board approved a grant of 200,000 incentive restricted stock units (RSUs) to CEO and director Sebastien Plouffe, vesting immediately on April 24, 2026. Each RSU converts to one common share and expires April 24, 2027, subject to the Omnibus Incentive Plan and securities law hold periods.
Defence Therapeutics (OTCQB: DTCFF) announced an amendment to 800,000 Common Share purchase warrants issued in a 2024 private placement.
The amendment extends each warrant expiry by 12 months and reprices the exercise price to $0.75 per share (from $1.00). The split is 775,000 and 25,000 warrants with new expiries of October 30, 2027 and November 29, 2027 respectively. None have been exercised. All other warrant terms remain unchanged and the changes are subject to final approval of the Canadian Securities Exchange; compensation and finder warrants are not eligible for amendment.
Defence Therapeutics (OTCQB: DTCFF) closed a private placement of 17,445,455 Units at $0.55 per Unit for aggregate gross proceeds of $9,595,000.25 on March 6, 2026. Each Unit includes one common share and one Warrant exercisable at $0.65 per share for 24 months.
The Company received $6,000,000 from two institutional investors under a binding term sheet; those 10,909,091 Warrants contain a 9.99% equity blocker. Investors received a corporate finance fee of 654,546 Units and a non-refundable deposit of 118,182 Units. Proceeds will fund ADC and radiopharmaceutical programs, partnerships, and working capital.
Defence Therapeutics (OTCQB:DTCFF) will showcase its proprietary Accum intracellular delivery platform at multiple international life‑science events in March 2026, including BIO‑Europe Spring (Mar 23‑26, Lisbon) and DCAT Week (Mar 23‑26, New York).
The company will pursue strategic partnerships, biomanufacturing discussions, and U.S. investor outreach at additional events in Miami (Mar 24) and FII PRIORITY Miami (Mar 25‑27), and has joined DCAT and BioFlorida to support commercial readiness for Accum.
Defence Therapeutics (OTCQB:DTCFF) launched a private placement of up to 20,000,000 Units at $0.55 for aggregate gross proceeds up to $11,000,000. Each Unit includes one share and one warrant exercisable at $0.65 for 24 months.
The company executed a binding term sheet for $6,000,000 CAD from two institutional investors with proceeds held in escrow and released as monthly cash tranches of $333,333 CAD over 18 months, subject to a sharing agreement that ties monthly share releases to a $0.7332 CAD benchmark price.
Defence Therapeutics (OTCQB: DTCFF) convened a Scientific Advisory Board on January 30, 2026 to align its Accum ADC strategy for improved intracellular payload delivery. Advisors with ADC chemistry, translational science, and partnering expertise informed prioritization of key experiments, data alignment for future clinical translation, and partnering readiness.
The SAB feedback is guiding a refined Accum ADC development roadmap aimed at enabling more effective, better-tolerated ADC therapies and positioning the platform for strategic collaborations.
Defence Therapeutics (OTCQB: DTCFF) will present at World ADC Europe 2026 in London, February 23–26, 2026, showcasing its proprietary Accum intracellular drug‑delivery platform.
The company said it will use the forum to engage potential partners, discuss co‑development of Accum‑enabled ADCs and precision oncology biologics, and schedule partnering meetings.
Defence Therapeutics (OTCQB:DTCFF) deepened its collaboration with Canadian Nuclear Laboratories to accelerate its proprietary radiopharmaceutical pipeline. The expanded partnership will initiate multiple radioisotope programs using Defence's Accum platform as lead program data aim to support candidate selection and prepare for first-in-human studies.
The move positions Defence to broaden radiopharmaceutical assets alongside its ADC work and leverage CNL nuclear science expertise to advance programs toward the clinic.
Defence Therapeutics (OTCQB: DTCFF) said it is repositioning as a precision intracellular drug-delivery company centered on its proprietary Accum platform.
The company says Accum enhances cellular uptake and payload release to boost therapeutic potency at lower doses and potentially reduce toxicity. Defence plans a dual strategy of internal R&D plus strategic partnerships to apply Accum to antibody-drug conjugates, radiopharmaceuticals and other complex biologics, with the stated goal of enabling safer, earlier-line cancer treatments and creating scalable value for partners and shareholders.
Defence Therapeutics (OTCQB: DTCFF) reported results from its December 10, 2025 annual meeting and provided corporate updates.
Shareholders approved a five-member board and ratified Crowe MacKay as auditors. The company granted 800,000 stock options exercisable at $0.82 for 10 years. Defence amended 967,000 warrants from private placements, extending expiry by 12 months and repricing exercise price from $2.00 to $1.00 (new expiries Jan 30, 2027 and Mar 22, 2027).
Defence disclosed a marketing services agreement with i2i Marketing Group for USD $300,000, starting ~Nov 3, 2025, with $50,000 paid on signing and remaining payments tied to completion conditions.